Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × sapacitabine × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Specimen Handling 117 Magnetic Resonance Spectroscopy 104 Biopsy 79 pembrolizumab 68 Carboplatin 64 Cyclophosphamide 54 Paclitaxel 49 Cisplatin 48 Radiotherapy 43 Nivolumab 41 Gemcitabine 39 Lenalidomide 35 Dexamethasone 35 Radiation 33 durvalumab 29 atezolizumab 29 Prednisone 29 Pemetrexed 28 Doxorubicin 28 Ipilimumab 27 Fluorouracil 27 Bevacizumab 27 Rituximab 25 olaparib 24 Vincristine 24 Taxes 24 venetoclax 23 Oxaliplatin 23 Etoposide 22 Docetaxel 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03641755 2026-02-23

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡